In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
  • Select congresses

    Select Select congresses(s)

  • Year

    Select Year(s)

  • Resource type

    Select Resource type(s)

  • Topic

    Select Topic(s)

Filters (0)
  • Select congresses
  • sub-topic
  • Year
  • Resource type
  • Topic
  • Select congresses
  • sub-topic
  • Year
  • Resource type
  • Topic

Sponsored content

Presentations below are part of sessions sponsored by Boehringer Ingelheim

185 results for your search

Advancing evidence-based care in patients with type 2 diabetes: new opportunities for cardiologists.

Congress : Heart Failure 2019

  • Session : Know it by heart - New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era
  • Speaker : R Fontes Carvalho (Porto,PT)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Introduction and welcome - The evolving role of cardiologists: can we help decrease the cardiovascular event burden in patients with type 2 diabetes?

Congress : Heart Failure 2019

  • Session : The evolving role of cardiologists: can we help decrease the cardiovascular event burden in patients with type 2 diabetes?
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Ongoing studies with SGLT2 inhibitors: how may new and emerging evidence inform future clinical practice?

Congress : Heart Failure 2019

  • Session : Know it by heart - New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era
  • Speaker : F Zannad (Vandoeuvre,FR)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Open questions and answers - The evolving role of cardiologists: can we help decrease the cardiovascular event burden in patients with type 2 diabetes?

Congress : Heart Failure 2019

  • Session : The evolving role of cardiologists: can we help decrease the cardiovascular event burden in patients with type 2 diabetes?
  • Speaker : J Butler (Atlanta,US), R Fontes Carvalho (Porto,PT)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

SGLT2 inhibitors: what is the evidence so far?

Congress : Heart Failure 2019

  • Session : Know it by heart - New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Summary and close - Know it by heart - New opportunities for cardiologists in the SGLT2 inhibitor era.

Congress : Heart Failure 2019

  • Session : Know it by heart - New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era
  • Speaker : F Ruschitzka (Zurich,CH), F Zannad (Vandoeuvre,FR)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Welcome and introduction - Know it by heart - New opportunities for cardiologists in the SGLT2 inhibitor era.

Congress : Heart Failure 2019

  • Session : Know it by heart - New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era
  • Speaker : F Ruschitzka (Zurich,CH)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Advancing the standard of care in patients with type 2 diabetes and established cardiovascular disease: how can we improve patient outcomes? .

Congress : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : N Marx (Aachen,DE), D Mcguire (Dallas,US), JA Udell (Toronto,CA), S Verma (Toronto,CA), N Sattar (Glasgow,GB)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Applying breakthroughs in AF ablation to your clinical practice.

Congress : EHRA 2018

  • Session : Uninterrupted dabigatran: exploring the impact on AF ablation
  • Speaker : D Gupta (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Applying evidence in practice: appropriate use of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in the cardiology clinic.

Congress : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : JA Udell (Toronto,CA), N Sattar (Glasgow,GB)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are